Roivant Sciences Ltd at Jefferies Global Healthcare Conference in New York Transcript
All right, welcome to the Jefferies Healthcare Conference. My name is Dennis Ding, biotech research analyst here at Jefferies. I have the great pleasure of having Matt Gline here, CEO of Roivant. Welcome.
Thanks for having me. It's great to be here.
Before we kind of get into Q&A, and there is certainly lots to talk about, I'd love to hand it over to you to just kind of give an overview. I mean, it's been incredibly -- I mean, Roivant's a $20 billion market cap company now.
It's true. Look, it's been a really great 12 months for us. Yeah, look, I think many of you know a little bit about our story, but we are roughly out there trying to do the same thing everybody else is, which is develop medicines that matter. And we've been very fortunate to have now
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
